Match Document Document Title
7521529 Differentially protected orthogonal lanthionine technology  
The present invention provides a method of synthesizing an intramolecularly bridged polypeptide comprising at least one intramolecular bridge. The present invention further provides a method of...
7521415 Methods of intracellular peptide delivery  
Methods and kits for transporting heterologous compounds into cells, particularly mammalian cells, are disclosed. The method involves the pretreatment of the cell with a polycation, cationic...
7517654 Peptide and a derivative thereof promoting cell adhesion and spreading  
The present invention relates to a peptide promoting cell adhesion and spreading, fragments, and derivatives thereof, more particularly, integrin-α3β1-dependent peptide in human laminin-5 α3...
7517855 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof  
The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell...
7514407 Spheron component peptides and pharmaceutical compositions  
The present invention relates to racemized proteins and racemized protein components of spherons that are useful for identifying compounds capable of preventing and/or ameliorating symptoms of...
7511012 Myostatin binding agents  
The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one...
7507717 Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)  
An isolated, synthetic or recombinant X-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5...
7507718 Polymyxin B analogs for LPS detoxification  
The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and...
7504381 Antimicrobial agents  
A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking there...
7501397 Helical peptidomimetics with enhanced activity  
Helical peptidomimetic compounds as inhibitors of beta-amyloid production are provided. These inhibitors have sequences with lengths from 11 to 16 amino acids, inclusive. These inhibitors potently...
7501398 Inhibitor of the folding of the HIV-1-protease as antiviral agent  
The invention relates to the design of inhibitors of the HIV-1-PR homodimer which do not create resistance, by blocking the folding of single monomers with the help of peptides which attach to...
7498306 Peptides binding to the phosphatase 2A protein  
The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids...
7498404 Compositions, methods and uses for a novel family of peptides  
The present invention includes compositions and methods for the characterization and use of novel peptide from Brevibacillus sp., and peptides related thereto, including an isolated and purified,...
7494979 Method for treating congestive heart failure and other disorders  
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders,...
7491701 Peptides that bind to HSP90 proteins  
YSLPGYMVKKLLGA (SEQ ID NO:1) and its active analogs, compositions, and methods of use.
7491699 Peptide nanostructures and methods of generating and using the same  
A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids...
7491690 Self-assembly and mineralization of peptide-amphiphile nanofibers  
Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.
7491691 Connective tissue stimulating peptides  
Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or...
7488793 Isolated peptide which binds to HLA-Cw*07 and uses thereof  
Peptides which consist of amino acid sequences found in MAGEA3 bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this...
7488717 Methods of inhibiting chemokine binding to chemokine receptors  
Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed...
7485321 Peyer's patch and/or M-cell targeting ligands  
Purified synthetic polypeptide ligands for targeting pharmaceutical agents and carriers comprising such agents to intestinal epithelial tissue, especially Peyer's patch and/or M-Cell tissue. Also...
7482433 Peptides and compounds that bind to the IL-5 receptor  
Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCR, GYVX 3 VEX 4 ARCPTCG, EGYVX 3 VEX 4 ARCPTCG,...
7482429 Kahalalide F and related compounds  
A process is provided for preparing kahalalide F and which leads to other kahalalide mimic compounds having useful biological activity.
7479483 Tumor-targeted drug delivery systems and uses thereof  
The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the...
7476656 Fluorescent affinity tag to enhance phosphoprotein detection and characterization  
The invention relates to target-associative tags incorporating cysteamine as the target-associative moiety. The invention further relates to a method for producing a target-associative tag by...
7473682 Angiogenic peptides and uses thereof  
A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also...
7473679 Treatments employing neuronal exocytosis-inhibiting peptides  
The peptide has a sequence of 3 to 30 adjacent amino acids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain...
7465708 Branched cationic copolymers and methods for antimicrobial use  
The invention provides a branched copolymer for the treatment of bacterial, fungal, and viral infections. The branched copolymer is characterized as having (i) at least 10 amino acids, (ii) at...
7462462 Peptide capable of binding to nanographite structures  
It is intended to provide a peptide or a phage recognizing nanographite structures and thus enabling efficient recognition, binding, separation and alignment of nanographite structures such as...
7462360 Alloferons—immunomodulatory peptides  
The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.
7456252 Therapeutic peptides for demyelinating conditions  
The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.
7452867 Use of ADNF polypeptides for treating peripheral neurotoxicity  
This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also...
7439228 Bioactive peptides  
The present invention provides a cytotoxic 7 to 25-mer peptide with three or more catonic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides,...
7438890 Binding peptides for carcinoembryonic antigen (CEA)  
The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens...
7435716 Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia  
Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing...
7435721 Transport peptides such as C-terminal Erns peptide and analogues thereof  
The invention relates to peptides derived from or similar to the E rns protein of pestiviruses for type-specific diagnosis of infection, for eliciting antibiotic activity, and for transport of...
7435718 CXCR4 antagonist treatment of hematopoietic cells  
In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication,...
7435790 Dihydroxypropyl cysteine peptide and agent containing this peptide  
The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following...
7432246 Sir2 products and activities  
A novel compound, 2′/3′-O-acetyl-ADP-ribose, is provided. The compound is a mixture of the 2′ and 3′ regioisomers of O-acetyl-ADP ribose, and is formed nonenzymatically from...
7425541 Enzyme-cleavable prodrug compounds  
The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is...
7423114 GD2 ligands  
The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY;...
7417025 Use of poly-α2,8-sialic acid mimetic peptides to modulate NCAM functions  
The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a...
7417023 Targeted delivery of bioaffecting compounds for the treatment of cancer  
A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the...
7414023 Peptide ligands for prostate specific antigen  
The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these...
7410950 Peptides of CaV2.2 that inhibit pain  
The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the...
7410949 Neuropeptide-2 receptor (Y-2R) agonists and uses thereof  
Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R 1 —R 2 —X—R 3 —R 4 —R 5 —R 6 —R 7 —R 8...
7408025 Lipopeptides as antibacterial agents  
The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial...
7402653 Biologically active peptides  
Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced...
7399826 Peptide for promoting healing of fractures  
The peptide for promoting healing of fractures is a 13-amino acid peptide which is sequenced and synthesized in the laboratory. The peptide SHMSP has the sequence represented by the formula...
7396815 Cosmetic or pharmaceutical composition containing peptides  
A cosmetic and/or dermatological and/or pharmaceutical composition includes, as the active ingredient, at least one peptide with sequence X 1 -Y-Phe-Thr-X 2 -Ala-Thr-Z-Ile-X 3 -Leu-X 4 -Phe-Leu-X 5...